PL2627346T3 - Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu zapalenia błony naczyniowej oka - Google Patents

Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu zapalenia błony naczyniowej oka

Info

Publication number
PL2627346T3
PL2627346T3 PL11775734.4T PL11775734T PL2627346T3 PL 2627346 T3 PL2627346 T3 PL 2627346T3 PL 11775734 T PL11775734 T PL 11775734T PL 2627346 T3 PL2627346 T3 PL 2627346T3
Authority
PL
Poland
Prior art keywords
uveitis
cell
treatment
signal transduction
transduction pathway
Prior art date
Application number
PL11775734.4T
Other languages
English (en)
Inventor
Jean-Marc Combette
Catherine Deloche
Claire Abadie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/006284 external-priority patent/WO2012048721A1/en
Application filed filed Critical
Publication of PL2627346T3 publication Critical patent/PL2627346T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11775734.4T 2010-10-14 2011-10-14 Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu zapalenia błony naczyniowej oka PL2627346T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2010/006284 WO2012048721A1 (en) 2010-10-14 2010-10-14 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
EP2011000307 2011-01-25

Publications (1)

Publication Number Publication Date
PL2627346T3 true PL2627346T3 (pl) 2016-11-30

Family

ID=44862926

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11775734.4T PL2627346T3 (pl) 2010-10-14 2011-10-14 Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu zapalenia błony naczyniowej oka
PL14004427T PL2902035T3 (pl) 2010-10-14 2011-10-14 Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu chorób zapalnych oka

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14004427T PL2902035T3 (pl) 2010-10-14 2011-10-14 Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu chorób zapalnych oka

Country Status (7)

Country Link
EP (2) EP2902035B1 (pl)
CY (1) CY1120936T1 (pl)
DK (2) DK2627346T3 (pl)
ES (2) ES2575226T3 (pl)
HK (1) HK1210056A1 (pl)
PL (2) PL2627346T3 (pl)
WO (1) WO2012048893A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) * 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2015197098A1 (en) * 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206563A2 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
AU2015281361A1 (en) * 2014-06-26 2016-11-17 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
DE102016111708A1 (de) 2016-06-27 2017-12-28 Heiko Schmidt Gelenkanordnung, vorgefertigte Baugruppe sowie Verfahren zur Herstellung einer vorgefertigten Baugruppe einer Gelenkanordnung
CN108060223A (zh) * 2017-12-29 2018-05-22 北京泱深生物信息技术有限公司 Atf2基因的新应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
PT671923E (pt) 1992-10-09 2001-10-30 Advanced Tissue Sciences Inc Celulas de reserva do figado
DE69637147T2 (de) 1995-07-28 2008-03-06 Marie Curie Cancer Care Transportproteine und deren verwendungen
AU2003294312A1 (en) * 2002-11-18 2004-07-09 Celgene Corporation Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
WO2008006046A1 (en) * 2006-07-06 2008-01-10 Case Western Reserve University Ceramide composition and use thereof in treatment of ocular diseases
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EA201171188A1 (ru) * 2009-03-30 2012-05-30 Сантен Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое средство против болезни сетчатки и способ профилактики или лечения болезни сетчатки с использованием jnk (c-jun-аминоконцевая киназа)-ингибиторного пептида, а также применение указанного пептида

Also Published As

Publication number Publication date
WO2012048893A1 (en) 2012-04-19
ES2575226T3 (es) 2016-06-27
DK2627346T3 (en) 2016-06-13
EP2627346A1 (en) 2013-08-21
EP2902035A1 (en) 2015-08-05
CY1120936T1 (el) 2019-12-11
HK1210056A1 (en) 2016-04-15
PL2902035T3 (pl) 2019-04-30
HK1187266A1 (zh) 2014-04-04
EP2627346B1 (en) 2016-03-23
DK2902035T3 (en) 2018-09-24
ES2688030T3 (es) 2018-10-30
EP2902035B1 (en) 2018-06-20

Similar Documents

Publication Publication Date Title
PL2489361T3 (pl) Zastosowanie przechodzących przez komórkę peptydowych inhibitorów szlaku przekazywania sygnałów przez JNK do leczenia różnych chorób
PL2902035T3 (pl) Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu chorób zapalnych oka
IL252108A0 (en) cdk inhibitors
IL232699A0 (en) Use of cell-permeable peptide inhibitors of signal transmitters in the jnk pathway to treat dry eye syndrome
IL222361A (en) Demethylase-1 inhibitors for lysine and their use
IL221311A0 (en) Inhibitors of protein kinases
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
PL3178818T3 (pl) Inhibitory kinazy pirazolilochinoksalinowej
GB201701948D0 (en) Releasable corrosion inhibitors
ZA201206456B (en) Uses of dgati inhibitors
GB201016880D0 (en) Phosphodiesterase inhibitors
EP2242501A4 (en) THERAPEUTIC INHIBITORS OF PAI-I FUNCTION AND METHODS OF USE
IL226005A0 (en) Inhibitors of cell death and uses thereof
IL217756A0 (en) Inhibitors of jnk
IL208916A0 (en) Inhibitors of jnk
ZA201300012B (en) Synthesis and use of kinase inhibitors
ZA201300009B (en) Oral formulation of kinase inhibitors
GB0803895D0 (en) Inhibitors of glyoxalase
LU91725B1 (en) Novel uses of V-ATPASE inhibitors
GB0801939D0 (en) Peptide inhibitors of lentiviral replication
GB0908609D0 (en) New use of isoQC inhibitors
GB201017098D0 (en) Carbonic anhydrase inhibitors
GB201002412D0 (en) Carbonic anhydrase inhibitors
GB201003949D0 (en) Inhibitors of protein kinases
HK1184156A (en) Synthesis and use of kinase inhibitors